济南那里有治疗痛风的医院济南降尿酸吃什么水果和蔬菜,山东一个手指疼痛是痛风吗,济南痛风得症状早期图片,济南怎么治疗痛风疼痛,济南痛风如何锻炼身体,济南痛风可以吃构枸杞吗,山东治痛风的简单方法

The woman who became internet famous in October for flipping the bird at President Donald Trump's motorcade, and then said she was subsequently fired, is suing her former employer for unlawful termination.Juli Briskman was fired from the marketing team at Akima LLC in November shortly after she volunteered that she was the one who had made the gesture in a photo that went viral, she said at the time."I thought that it would probably get back to my company eventually," Briskman said in an interview with CNN's Jeanne Moos.She said she was told she had violated the company's social media policy, and said the company in turn fired her.Briskman tweeted Wednesday that "I was fired from my job for flipping off @realDonaldTrump. Today, I filed suit with @GellerLawyers & @protctdemocracy because what happened to me was unlawful and un-American."Her attorney, Maria Simon, reiterated this point in a statement through the nonprofit Protect Democracy,"Juli's expression of disapproval of the President is fundamental political speech protected by both the United States Constitution and Virginia state law," she said. "Akima's actions -- forcing Juli to resign out of fear of unlawful retaliation by the government -- violated the basic tenets of Virginia employment law. Ms. Briskman chose in her private time and in her capacity as a private citizen to express her disapproval of President Trump by extending her middle finger."CNN has reached out to Akima LLC seeking comment. 1512

The U.S. experienced its largest single-day increase in new COVID-19 cases on Thursday according to figures from Johns Hopkins University.Johns Hopkins public database reports that about 40,000 confirmed cases of the coronavirus were reported to local health departments on Thursday. The previous one-day record for newly reported cases occurred on April 24, when about 36,000 were confirmed to have contracted the virus.According to Johns Hopkins, 2.4 million Americans have contracted the virus, and more than 124,000 have died after contracting it.A graph showing the number of new cases of COVID-19 reported each day in the U.S. (Johns Hopkins)New cases of the coronavirus are currently on the rise in several regions throughout the country. While top federal officials, including President Donald Trump, have maintained that the increase in cases can be attributed to an increase in testing, other concerning statistics, like hospitalizations linked to the virus, are also on the rise.On Thursday, Texas paused efforts to lift lockdown restrictions put in place earlier this year to prevent the spread of the virus. Other local governments have enacted mandates requiring masks in public.Vice President Mike Pence will hold a press conference along with the White House coronavirus task force on Friday in response to the rising case numbers. 1355

The White House has once again lowered the American flag to half-staff, after the flag was left at its full height for most of the day on Monday.In a statement released at about 4 p.m. ET, President Trump ordered flags be flown at half-staff until Sunday, the day of McCain's internment at the U.S. Naval Academy in Annapolis. The Trump administration faced criticism from politicians across party lines for choosing to fly the flag at full-staff while the rest of the federal government continued to honor Senator John McCain by keeping the flag low. Ohio Gov. John Kasich called the decision to keep the flags flying high "shameful."While protocol calls for the flag to be flown at half-staff the day and the day after a member of Congress dies, recent tradition has kept the flag at half-staff until sunset on the day of member's interment.   868

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

The Vans Warped Tour, a long-running punk rock tour and festival that pushed the genre into national relevance, will end after 2018.Warped Tour founder Kevin Lyman shared the news on the tour's website, in an essay headlined "All Good Things Must Come to an End.""It will be bittersweet each morning when I see the sun rise and then watch it set knowing that this will be the last time I get to witness it from that exact spot," Lyman wrote. "Though the tour and the world have changed since ’95, the same feeling of having the ‘best summer ever’ will live on through the bands, the production teams, and the fans that come through at every stop."The Warped Tour has been a summer staple in American cities since 1995. Each year, festival tour featured dozens of acts and multiple stages throughout cities in North America. Acts like Fall Out Boy, Blink-182, The Offspring, Simple Plan and Sum 41 got their start on the tour and helped start a pop punk revolution in the late '90s and early 2000sThough Lyman said the 2018 tour would be the festival's last, he also wrote that he is currently preparing a 25th anniversary celebration for the first Warped Tour in 2019.The cities and dates of the final Warped Tour are listed below. 1259